Filippo Pietrantonio Selected Research

Stomach Neoplasms (Stomach Cancer)

1/2022	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
4/2021	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S.
1/2021	Personalized therapeutic strategies in HER2-driven gastric cancer.
1/2020	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials.
1/2020	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
12/2019	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.
11/2019	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
11/2019	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits.
3/2019	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
1/2019	The landscape of d16HER2 splice variant expression across HER2-positive cancers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Filippo Pietrantonio Research Topics

Disease

110	Colorectal Neoplasms (Colorectal Cancer) 11/2022 - 01/2010
59	Neoplasms (Cancer) 04/2022 - 09/2011
26	Stomach Neoplasms (Stomach Cancer) 01/2022 - 06/2012
16	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2012
14	Disease Progression 10/2022 - 11/2010
13	Microsatellite Instability 01/2022 - 12/2016
6	Adenocarcinoma 01/2022 - 08/2016
5	Colonic Neoplasms (Colon Cancer) 01/2020 - 09/2013
3	Rectal Neoplasms (Rectal Cancer) 08/2021 - 01/2013
3	Pseudomyxoma Peritonei 01/2019 - 01/2016
2	Turcot syndrome 01/2022 - 12/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 09/2011
2	Neutropenia 01/2022 - 01/2021
2	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 01/2020
2	Inflammation (Inflammations) 01/2021 - 01/2020
2	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 01/2019
2	Melanoma (Melanoma, Malignant) 01/2020 - 12/2015
2	Breast Neoplasms (Breast Cancer) 01/2019 - 12/2014
1	Exanthema (Rash) 11/2022
1	Anemia 11/2022
1	Cholangiocarcinoma 10/2022
1	Hypertension (High Blood Pressure) 02/2022
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2022
1	Frailty 01/2022
1	Febrile Neutropenia 01/2022
1	Ascites 01/2022
1	Myocardial Infarction 01/2022
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2022
1	Carcinoma (Carcinomatosis) 11/2021
1	COVID-19 03/2021

Drug/Important Bio-Agent (IBA)

31	Biomarkers (Surrogate Marker)IBA 02/2022 - 03/2012
25	Bevacizumab (Avastin)FDA Link 02/2022 - 02/2011
21	Panitumumab (Vectibix)FDA Link 11/2022 - 12/2013
18	Cetuximab (Erbitux)FDA Link 04/2022 - 12/2013
16	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 01/2010
16	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 12/2014
13	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 06/2012
13	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2016
13	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
12	Leucovorin (Folinic Acid)FDA Link 01/2022 - 04/2016
10	Capecitabine (Xeloda)FDA Link 01/2020 - 06/2012
9	Temozolomide (Temodar)FDA LinkGeneric 10/2022 - 12/2014
8	Monoclonal AntibodiesIBA 11/2021 - 09/2015
8	Biological ProductsIBA 01/2020 - 02/2011
7	Pharmaceutical PreparationsIBA 02/2022 - 01/2010
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2013
5	PlatinumIBA 10/2022 - 01/2013
5	regorafenibIBA 01/2022 - 01/2020
5	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2014
5	Docetaxel (Taxotere)FDA Link 04/2021 - 04/2016
4	Calcibiotic Root Canal SealerIBA 01/2022 - 01/2016
4	avelumabIBA 01/2022 - 10/2021
4	trifluridine tipiracil drug combinationIBA 01/2022 - 11/2017
4	Epidermal Growth Factor (EGF)IBA 01/2022 - 09/2019
4	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 04/2016
3	MethyltransferasesIBA 10/2022 - 12/2014
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2018
3	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2018
3	Trastuzumab (Herceptin)FDA Link 01/2021 - 01/2018
3	Alkylating AgentsIBA 01/2020 - 12/2014
3	EnzymesIBA 12/2019 - 12/2016
3	Phosphotransferases (Kinase)IBA 10/2019 - 08/2017
3	afliberceptIBA 11/2018 - 11/2018
2	encorafenibIBA 04/2022 - 01/2020
2	atezolizumabIBA 01/2022 - 07/2020
2	Circulating Tumor DNAIBA 01/2021 - 12/2019
2	Trifluridine (Viroptic)FDA LinkGeneric 05/2020 - 11/2017
2	AntibodiesIBA 01/2020 - 01/2016
2	RamucirumabIBA 03/2019 - 01/2018
2	Paclitaxel (Taxol)FDA LinkGeneric 03/2019 - 01/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2017 - 08/2014
2	Vinorelbine (Navelbine)FDA LinkGeneric 01/2017 - 11/2010
2	XELOXIBA 12/2014 - 01/2012
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2022
1	IpilimumabIBA 10/2022
1	NivolumabIBA 10/2022
1	pembrolizumabIBA 01/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022
1	Anaplastic Lymphoma KinaseIBA 01/2022
1	Angiopoietin-2IBA 01/2022
1	CTLA-4 AntigenIBA 01/2022
1	SaltsIBA 01/2022
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 08/2021
1	Doxycycline (Periostat)FDA LinkGeneric 07/2021
1	durvalumabIBA 06/2021
1	tremelimumabIBA 06/2021
1	SynaptophysinIBA 01/2021
1	Lapatinib (GW572016)FDA Link 01/2021

Therapy/Procedure

56	Therapeutics 01/2022 - 02/2011
42	Drug Therapy (Chemotherapy) 11/2022 - 11/2010
5	Immunotherapy 01/2022 - 01/2020
5	Neoadjuvant Therapy 08/2021 - 01/2013
5	Adjuvant Chemotherapy 04/2021 - 04/2014
3	Hyperthermic Intraperitoneal Chemotherapy 04/2018 - 01/2016
3	Radiotherapy 12/2014 - 09/2011
2	Retreatment 01/2022 - 01/2020
2	Salvage Therapy 05/2020 - 01/2014
2	Precision Medicine 11/2019 - 10/2019
2	Cytoreduction Surgical Procedures 01/2017 - 01/2016
1	Duration of Therapy 01/2021